MedTrace Logo

From the Emergency Department Directly to Ablation of Atrial Fibrillation Study

NCT05294445 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2026-05-22

No results posted yet for this study

Summary

The study is a prospective, two-arm, randomized, open-label, blinded endpoint, multi-center study to investigate the impact of first line ablation in patients presenting at the emergency room with recent-onset paroxysmal or persistent atrial fibrillation.

Conditions

  • Atrial Fibrillation (AF)

Interventions

PROCEDURE

Ablation of atrial fibrillation (AF)

Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)

Sponsors & Collaborators

  • Atrial Fibrillation Network

    collaborator OTHER

  • Medtronic Bakken Research

    collaborator INDUSTRY

  • Asklepios proresearch

    lead INDUSTRY

Principal Investigators

  • Stephan Willems, MD, PhD · Asklepios Hospital St. Georg, Hamburg, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2026-12-14
Completion
2028-12-14

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05294445 on ClinicalTrials.gov